688 / 1068
NSAPB R-04
Inclusion criteria: cT3-4 or N+ M0
R
RT 50.4 Gy (@1.8Gy) +
5-FU c.i. 225 mg/m
2
/d
+/-
Oxaliplatin 50 mg/m
2
weekly
T
M
E
Adjuvant
treatment
not
specified
Primary endpoint: Time to locoregional failure
Secondary:
pCR, sphincter-sparing surgery, downstaging, tox
T
M
E
Adjuvant
treatment
not
specified
RT 50.4 Gy (@1.8Gy) +
Capecitabine 1600 mg/m
2
/d 5d/w
+/-
Oxaliplatin 50 mg/m
2
weekly